MOTS-c: Mitochondrial Peptide, Metabolism & Exercise Mimetic Research

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene of mitochondrial DNA (mtDNA). It was discovered in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California’s Leonard Davis School of Gerontology, who published the landmark identification study in Cell Metabolism.

The discovery of MOTS-c was significant for several reasons. First, it expanded the concept of mitochondria from mere “powerhouses of the cell” to active signaling organelles that communicate with the nucleus and other cellular systems through secreted peptides. Second, MOTS-c was identified as only the second mitochondrial-derived peptide (MDP) — after humanin, discovered in 2001 — opening an entirely new category of biologically active molecules. Since then, the MDP family has grown to include additional members (SHLPs 1-6), but MOTS-c and humanin remain the most extensively studied.

What makes MOTS-c particularly compelling in the metabolic research space is its characterization as an “exercise mimetic” — a molecule that activates cellular energy-sensing pathways normally engaged during physical exercise, without the mechanical stimulus of exercise itself. This property has generated significant interest in the contexts of metabolic disease, aging, and conditions where exercise capacity is limited.

Mitochondrial-Derived Peptides: A New Signaling Paradigm

The mitochondrial genome (mtDNA) is a 16,569-base-pair circular DNA molecule that was traditionally thought to encode only 13 proteins — all components of the electron transport chain — along with 22 tRNAs and 2 rRNAs. The discovery that mtDNA also encodes bioactive signaling peptides within previously “non-coding” regions revealed an unexpected layer of mitochondrial communication.

MOTS-c is encoded within the 12S rRNA gene, which was not previously thought to contain protein-coding sequences. Its discovery was made possible by computational screening for short open reading frames (sORFs) within the mitochondrial genome, followed by functional validation. The peptide sequence is MRWQEMGYIFYPRKLR, and it has been detected in human plasma, indicating that it is secreted from cells and functions as a circulating signaling factor.

This retrograde signaling — from mitochondria to nucleus — has been termed “mitochondrial retrograde communication” or “mito-nuclear crosstalk.” MOTS-c represents one of the few known molecular mediators of this process, positioning it at the intersection of mitochondrial biology, metabolism, and aging research.

How MOTS-c Works: Mechanism of Action

Research has identified several interconnected mechanisms through which MOTS-c exerts its metabolic effects:

• AMPK pathway activation — The AMP-activated protein kinase (AMPK) is the cell’s primary energy sensor, activated when the AMP/ATP ratio increases (indicating energy depletion). MOTS-c activates AMPK through inhibition of the folate-methionine cycle, which leads to accumulation of the intermediate AICAR — an endogenous AMPK activator. This is the same pathway engaged during exercise, which is why MOTS-c has been characterized as an exercise mimetic. AMPK activation triggers downstream effects including enhanced glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and autophagy.
• Folate-methionine cycle modulation — MOTS-c inhibits specific enzymes in the de novo purine biosynthesis pathway that interfaces with the folate cycle. This metabolic bottleneck leads to AICAR accumulation and AMPK activation. Importantly, this mechanism acts upstream of AMPK itself, providing a physiological route of activation rather than direct pharmacological AMPK stimulation.
• Nuclear translocation under stress — A remarkable finding published in 2019 revealed that MOTS-c translocates to the nucleus under metabolic stress conditions. Once in the nucleus, MOTS-c interacts with transcription factors and chromatin to regulate the expression of genes involved in the adaptive stress response — particularly antioxidant response element (ARE)-dependent genes. This represents a direct mitochondria-to-nucleus signaling pathway mediated by a peptide.
• Glucose metabolism regulation — MOTS-c has been shown to enhance glucose uptake in skeletal muscle cells through increased GLUT4 translocation to the cell membrane — the same mechanism by which insulin and exercise promote glucose disposal. This effect is AMPK-dependent and occurs independently of insulin signaling, suggesting a potential insulin-sensitizing mechanism.
• Fatty acid oxidation — AMPK activation by MOTS-c promotes fatty acid oxidation through inhibition of acetyl-CoA carboxylase (ACC), which reduces malonyl-CoA levels and relieves inhibition of carnitine palmitoyltransferase 1 (CPT1) — the rate-limiting step in fatty acid transport into mitochondria for beta-oxidation.
• Mitochondrial biogenesis — Chronic AMPK activation stimulates PGC-1α expression, the master regulator of mitochondrial biogenesis. Research has documented increased mitochondrial content and improved mitochondrial function markers in MOTS-c-treated cells and tissues.

Metabolic Research

Obesity and Body Composition Studies

The original 2015 discovery paper included striking metabolic findings in mouse models. Mice receiving MOTS-c injections showed:

• Prevention of age-dependent and high-fat-diet-induced obesity
• Reduced fat mass accumulation without significant changes in food intake
• Improved glucose tolerance and insulin sensitivity
• Enhanced fatty acid oxidation in skeletal muscle

Subsequent studies have replicated these findings in multiple rodent models, including diet-induced obesity (DIO) and genetic obesity models. The consistent observation is that MOTS-c administration shifts energy metabolism toward fatty acid oxidation while enhancing glucose disposal — a metabolic profile that mirrors the adaptations seen with endurance exercise training.

Insulin Sensitivity and Glucose Homeostasis

MOTS-c has been investigated in models of insulin resistance and type 2 diabetes. Key findings include:

• Improved glucose tolerance test results in insulin-resistant mice
• Enhanced insulin-stimulated glucose uptake in skeletal muscle ex vivo
• Reduced hepatic glucose output, suggesting effects on liver metabolism in addition to skeletal muscle
• Decreased circulating levels of pro-inflammatory cytokines associated with metabolic syndrome

A 2019 study investigated MOTS-c in a streptozotocin-induced diabetes model and reported improvements in blood glucose regulation, reduced oxidative stress markers, and improved beta-cell function parameters.

MOTS-c as an Exercise Mimetic

The characterization of MOTS-c as an exercise mimetic is based on its activation of the same signaling cascade (AMPK → PGC-1α → mitochondrial biogenesis) engaged during aerobic exercise. A 2020 study published in Nature Communications by Lee’s group provided direct evidence for this connection:

• Circulating MOTS-c levels in human subjects increased during exercise, with peak levels correlating with exercise intensity
• MOTS-c levels were higher in physically active individuals compared to sedentary controls
• Skeletal muscle MOTS-c expression increased in response to exercise training
• The study proposed that MOTS-c functions as an exercise-responsive mitokine — a signaling molecule released by mitochondria in response to metabolic demand

This exercise mimetic property has generated particular interest for populations where exercise capacity is limited, such as the elderly, those with mobility impairments, or in post-surgical recovery contexts. The intersection of exercise mimesis and recovery research connects MOTS-c to the broader catalog of metabolic peptides including AOD-9604 and 5-Amino-1MQ.

Aging Research

Age-Related MOTS-c Decline

A consistent finding across studies is that endogenous MOTS-c levels decline with age. Human plasma MOTS-c concentrations decrease significantly between young adulthood and old age, paralleling the decline in mitochondrial function and metabolic flexibility that characterizes aging. This age-related decline has led researchers to propose that MOTS-c depletion may contribute to the metabolic dysfunction, insulin resistance, and reduced exercise capacity observed in aging.

Healthy Aging Models

In aged mouse models, MOTS-c administration has been associated with:

• Improved physical performance on treadmill testing
• Better glucose tolerance and insulin sensitivity
• Reduced markers of systemic inflammation
• Enhanced skeletal muscle function and reduced sarcopenia-related changes
• Improved thermoregulation — aged mice treated with MOTS-c maintained body temperature better during cold challenge

Centenarian Studies

A fascinating epidemiological finding was the identification of a specific mtDNA variant (m.1382A>C) in the 12S rRNA gene that alters the MOTS-c peptide sequence. This variant, which results in a K14Q substitution in the MOTS-c peptide, was found to be enriched in Japanese centenarians compared to the general population. Functional studies showed that the K14Q variant had distinct metabolic properties, suggesting that genetic variation in MOTS-c may contribute to human longevity.

Musculoskeletal Research

Skeletal Muscle

MOTS-c’s effects on skeletal muscle are consistent with its exercise mimetic profile. Research has documented:

• Increased expression of oxidative metabolism genes in muscle fibers
• Enhanced mitochondrial content and function in treated muscle tissue
• Improved muscle endurance capacity in functional tests
• Protection against age-related muscle mass loss (sarcopenia) markers

Bone Metabolism

An emerging area of MOTS-c research involves bone biology. A 2021 study published in Cell Metabolism reported that MOTS-c promoted osteoblast differentiation and bone formation in both cell culture and animal models. In ovariectomized mice (a model of postmenopausal osteoporosis), MOTS-c administration was associated with preserved bone mineral density and improved bone microarchitecture. The mechanism appeared to involve AMPK-mediated regulation of osteoblast energy metabolism, consistent with MOTS-c’s broader metabolic signaling role.

Inflammatory and Immune Research

MOTS-c has demonstrated anti-inflammatory properties across multiple research models:

• NF-κB pathway modulation — MOTS-c has been shown to inhibit NF-κB activation, reducing the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
• Macrophage polarization — Similar to TB-500, MOTS-c has been observed to promote anti-inflammatory M2 macrophage polarization in some research models
• Inflammaging — The chronic low-grade inflammation associated with aging (“inflammaging”) is a target of particular interest for MOTS-c research, given the correlation between age-related MOTS-c decline and increased inflammatory markers

Dosing in Research Models

Research Context	Model	Dose	Route	Schedule
Obesity prevention	Mouse (HFD)	5 mg/kg	IP injection	Daily for 8–12 weeks
Glucose homeostasis	Mouse (DIO)	5–15 mg/kg	IP injection	Daily for 2–4 weeks
Aging studies	Aged mice (24 months)	5 mg/kg	IP injection	3×/week for 8 weeks
Bone studies	OVX mice	5 mg/kg	IP injection	Daily for 6–8 weeks
Cell culture	C2C12 myotubes	1–10 μM	Culture medium	24–72 hours

Reconstitution and Handling

• Storage — Lyophilized MOTS-c at -20°C for long-term stability; protect from light
• Reconstitution — Reconstitute with sterile bacteriostatic water. MOTS-c is water-soluble due to its charged amino acid composition.
• Stability — Reconstituted solution stable for approximately 14–20 days at 2–8°C. Avoid repeated freeze-thaw cycles.
• Note — MOTS-c contains a methionine residue that is susceptible to oxidation; minimize exposure to air and oxidizing agents during handling.

Safety Profile in Research

Published studies have reported favorable safety profiles for MOTS-c in preclinical models:

• No significant adverse effects at standard research doses (5–15 mg/kg in mice)
• No hypoglycemia observed — MOTS-c enhances glucose disposal under high-glucose conditions but does not appear to cause pathological glucose lowering under normal conditions
• As an endogenous human peptide, MOTS-c is processed through normal metabolic pathways
• No organ toxicity reported in subchronic administration studies

However, human safety data for exogenous MOTS-c administration is currently unavailable, and the long-term effects of chronically elevated MOTS-c levels have not been studied.

Current Limitations and Future Directions

• No human clinical trials — Despite compelling preclinical data, MOTS-c has not yet entered human clinical trials for any indication. The transition from animal studies to human testing is a critical gap in the evidence base.
• Short half-life — As a small peptide, MOTS-c is subject to rapid proteolytic degradation in vivo, which may limit its therapeutic utility without formulation optimization. Research into longer-acting analogs or sustained-release formulations is ongoing.
• Mechanistic complexity — The multi-pathway nature of MOTS-c signaling (AMPK, nuclear translocation, folate cycle modulation) makes it challenging to attribute specific effects to individual mechanisms.
• Dose extrapolation — The doses used in mouse studies (5 mg/kg) are relatively high and may not directly translate to equivalent human dosing.
• Sex-specific effects — Some studies have reported sex-dependent differences in MOTS-c response, potentially related to interactions between mitochondrial signaling and sex hormone pathways. This area requires further investigation.

Future research priorities include the initiation of human clinical trials, development of MOTS-c analogs with improved pharmacokinetic properties, investigation of MOTS-c in combination with exercise interventions, and deeper characterization of the nuclear translocation mechanism and its gene regulatory targets.

Summary

MOTS-c is a mitochondrial-derived peptide that functions as an endogenous exercise mimetic through AMPK pathway activation, metabolic stress adaptation, and nuclear gene regulation. Since its discovery in 2015, it has rapidly become one of the most actively studied peptides in metabolic and aging research, with compelling preclinical data spanning obesity, insulin resistance, aging, bone metabolism, and inflammation. Its unique origin as a mitochondrial genome-encoded signaling molecule — one that bridges mitochondrial function, cellular metabolism, and nuclear gene expression — positions MOTS-c at the forefront of mito-nuclear communication research. The transition from preclinical evidence to human clinical data represents the critical next step for this promising metabolic peptide.

View MOTS-c in our research catalog. Related metabolic research peptides: AOD-9604, 5-Amino-1MQ, and Retatrutide.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Kumagai et al.	2023	Review	MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation	PMC9905433
Lee et al.	2015	In Vivo	Mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity	PMID 25738459
Li & Laher	2022	Review	Exercise, mitohormesis, and MOTS-c signaling pathways	PMC9171157
Yin et al.	2023	Review	MOTS-c: effects and mechanisms related to stress, metabolism, and aging	PMC9854231
Ming et al.	2016	Review	MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism	PMC5116416
Dieli-Conwright et al.	2021	Clinical Study	Effect of aerobic and resistance exercise on MOTS-c in breast cancer survivors	PMC8376922
Abbasian et al.	2024	In Vivo	Effects of interval exercises on mitochondrial MOTS-c in diabetic sand rats	PMID 38636847

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.